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Abstract Rationale: In animal studies, the common
club drug 3,4-methylendioxymethamphetamine (MDMA,
“Ecstasy”) consistently caused a prolonged loss of
presynaptic serotonergic neurons, and evidence suggests
that MDMA consumption may also affect the human
serotonergic system. Serotonin (5-HT) has been implicated
in the regulation of impulsivity and such executive
functions as decision-making cognition. In fact, MDMA
users have shown elevated impulsivity in two studies, but
little is known about decision making in drug-free MDMA
consumers. Objective: The aim of this study was to
examine the cognitive neurotoxicity of MDMA with
regard to behavioral impulsivity and decision-making cog-
nition. Methods: Nineteen male, abstinent, heavy MDMA
users; 19 male, abstinent cannabis users; and 19 male,
drug-naïve controls were examined with the Matching
Familiar Figures Test (MFFT) as well as with a Go/No-Go
Task (GNG) for impulsivity and with a Gambling Task
(GT) for executive functioning. Results: MDMA users
showed significantly elevated impulsivity in the MFFT
Impulsivity score (I-score), but not in commission errors of
the GNG, compared with controls. Cannabis users did not
yield altered impulsivity compared with controls. In the GT,
MDMA users performed significantly worse than cannabis
consumers and controls, whereas cannabis users exhibited
the same decision-making capacity as controls. In addition,
the I-score as well as the decision-making performance was
correlated with measures of MDMA intake. The I-score and
the decision-making performance were also correlated.
Conclusion: These results suggest that heavy use of
MDMA may elevate behavioral impulsivity and impair
decision-making cognition possibly mediated by a selective
impairment of the 5-HT system.
Keywords MDMA . Cannabis . Impulsivity . Decision-
making cognition . Matching Familiar Figures Test .
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Introduction
3,4-Methylenedioxymethamphetamine (MDMA; “Ecsta-
sy”) is an illicit club drug that is widely abused, especially
by young people (Christophersen 2000). In a recent survey
from the Federal Centre for Health Education (BZgA) in
Germany, 4% of the interviewed juveniles between 12 and
25 years of age reported having used Ecstasy at least once
(BZgA 2004). Therewith, after cannabis (24%), MDMA
and derivatives rank second of the most popular illicit
drugs in Germany (BZgA 2004). Even worldwide, MDMA
has become one of the most widely used illegal psycho-
active drugs, with millions of regular users (Landry 2002).
In animals, administration of MDMA produces a rapid
and marked release of serotonin (5-HT) via inhibition and
reversal of the 5-HT transporter (Rudnick and Wall 1992).
Studies in nonhuman primates provided convincing evi-
dence that MDMA causes a substantial and sustained long-
term neurotoxic loss only of 5-HT nerve terminals, with an
associated depletion of up to 95% of 5-HT in several brain
regions, whereas other neurotransmitter systems such as
dopamine or norepinephrine remain undamaged (Insel et
al. 1989; Wilson et al. 1989; Ali et al. 1993; Scheffel et al.
1998; Hatzidimitriou et al. 1999; Taffe et al. 2002). Studies
of MDMA use in humans have also shown selective dec-
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rements in cerebrospinal fluid (CSF) concentrations of 5-
hydroxy indoleacetic acid (5-HIAA) as a marker for central
serotonergic depletion, with no alterations in CSF homo-
vanillic acid (HVA) or 3-methoxy-4-hydroxyphenylglycol
(MHPG), the major metabolites of dopamine and norepi-
nephrine, respectively (McCann et al. 1994, 1999). Imag-
ing studies with serotonergic radioligands exhibited
reduced 5-HT transporter densities in cortical and subcor-
tical structures of the brains of MDMA users (McCann et
al. 1998; Semple et al. 1999; Reneman et al. 2001; Buchert
et al. 2003). Furthermore, electrophysiological studies
suggested alterations of the serotonergic system in regular
users of MDMA (Tuchtenhagen et al. 2000; Croft et al.
2001a; Quednow et al. 2004). In summary, MDMA seems
to be a neurotoxin that selectively impairs the serotonergic
system in primates, including humans.
An important physiological role of the neurotransmitter
5-HT is behavioral inhibition. Previous animal and human
studies demonstrated that increasing central 5-HT function
inhibits aggression (Soubrié 1986; Morand et al. 1983);
conversely, low 5-HT neurotransmission is associated with
impulsive aggressive behavior in rodents, primates, and
humans (Soubrié 1986; Linnoila et al. 1983; Coccaro et al.
1989; Virkkunen et al. 1994). Indeed, evidence of low 5-
HT neurotransmission was reported to be involved in the
etiology of several disorders characterized by behavioral
disinhibition, including alcohol dependence, suicide, bulim-
ia, personality disorders, conduct disorder, and aggression
(LeMarquand et al. 1999). In addition, lowering serotonin
via tryptophan depletion increases impulsive behavior in rats
(Harrison et al. 1999; Winstanley et al. 2004) and healthy
individuals (Rogers et al. 1999a; Walderhaug et al. 2002).
Behavioral inhibition has been proposed as a critical com-
ponent of decision-making cognition (Monterosso and
Ainslie 1999; Cardinal et al. 2004; Deakin et al. 2004).
Moreover, behavioral inhibition as well as decision making
has been conceptualized as elements of executive function-
ing, and both were therefore linked to the functions of the
prefrontal cortex (Smith and Jonides 1999; Funahashi 2001;
Elliott 2003). It has been postulated previously that pre-
frontal 5-HT further plays a crucial role in executive func-
tions and especially decision making because patients with
focal prefrontal lesions as well as tryptophan-depleted
healthy volunteers demonstrated impaired decision-making
cognition (Rogers et al. 1999a,b, 2003).
It has been shown previously that MDMA users display
an elevated behavioral impulsivity in the Matching Familiar
Figures Test (MFFT) (Morgan 1998; Morgan et al. 2002).
Because of the correlation of MDMA intake with the
MFFT Impulsivity score (I-score), it was suggested that the
serotonergic neurotoxicity of MDMA caused these behav-
ioral deficits (Morgan 1998; Morgan et al. 2002). This as-
sumption is supported by animal data showing that repeated
MDMA administration leads to an increase in inappropriate
responses, indicating an elevation of impulsivity (Taylor and
Jentsch 2001). Studies with MDMA users applying self-
reported measures of impulsivity were not discussed here
because self-report inventories were not suitable for
measuring the state-dependent behavioral neurotoxicity
induced by illicit drugs (Dougherty et al. 2004).
There is evidence that MDMA use impairs memory
(e.g., Parrott et al. 1998; McCann et al. 1999; Morgan 1999;
Bhattachary and Powell 2001; Fox et al. 2001b, 2002;
Morgan et al. 2002; Gouzoulis-Mayfrank et al. 2003). It
was proposed that MDMA users also showed impaired
executive functions (McCann et al. 1999; Bhattachary and
Powell 2001; Fox et al. 2001a; Zakzanis and Young 2001;
Alting von Geusau et al. 2004). In most of the aforemen-
tioned studies, memory deficits and executive dysfunction
in MDMA users were assumed to be a consequence of the
serotonergic neurotoxicity of MDMA. As of yet, only one
study has assessed the decision-making cognition of MDMA
users, although decision-making tasks involve primarily
the 5-HT system, whereas classical executive function tasks
(e.g., working memory tasks, Tower of London, extradi-
mensional shift) implicate instead the dopaminergic or
noradrenergic system (Robbins 2000). However, Fox et al.
(2002) did not find changes in the Decision-Making Task
of Rogers et al. (1999a) in MDMA users.
The aim of this study was to further investigate the be-
havioral neurotoxicity of MDMA use with regard to dif-
ferent aspects of impulsivity and decision-making cognition.
Thus, we applied two common behavioral impulsivity
measures, the MFFT (Kagan et al. 1964) and the Go/No-Go
Task (GNG) (Newman and Kosson 1986), as well as a
Gambling Task (GT) (Bechara et al. 1994), for decision-
making cognition in chronic but recently abstinent MDMA
users compared with those attributes of a clinical control
group of cannabis users and healthy control sub jects with
no history of drug abuse. The comparison with a control
group of cannabis users allowed us to estimate the influence
of the common concomitant use of cannabis in MDMA
users, which is discussed in previous works as being a strong
biasing factor in research with MDMA consumers (Croft et
al. 2001b; Daumann et al. 2001; Gouzoulis-Mayfrank et al.
2002). Although the GNG according to Newman and
Kosson (1986) and the GT according to Bechara et al.
(1994) are well-established measures for impulsivity and
decision-making performance, they have not been used to
examine MDMA users so far. Because of the serotonergic
neurotoxicity of MDMA and the postulated involvement of
5-HT in impulsivity and decision-making cognition, we ex-
pected elevated levels of impulsivity and a decision-making
deficit in MDMA users in comparison with both control
groups. Due to the assumption that the supposed behavioral
deficits were caused by MDMA, we anticipated correlations
of MDMA consumption with impulsivity and decision-
making measures.
Materials and methods
Participants
Impulsivity and decision-making cognition were measured
in three groups. The first group (MDMA group) included
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19 male, drug-free, chronic users of MDMA; the second
group (cannabis group) consisted of 19 male, drug-free,
chronic users of cannabis; and the third group (drug-naïve
control subjects) comprised 19 male participants with no
history of illicit drug use. MDMA users were recruited by
advertisement in a techno music magazine. Cannabis users
and drug-naïve control subjects were recruited by adver-
tisement in a local newspaper. Subjects of the MDMA group
were required to have used MDMA at least 50 times over a
period of at least 1 year. In addition, the use of MDMA
clearly had to outweigh the consumption of any other psy-
chotropic drug. To be eligible for inclusion in the cannabis
group, participants should have no substantial previous use
of amphetamine derivatives like MDMA and no substantial
previous use of cocaine. Neuropsychological assessment
was carried out when participants were drug-free for at
least 3 days. Inclusion criteria for the drug-naïve control
subjects included negative urine drug test results. Legit-
imate use of psychotropic medication; a present psychiatric
illness; a family history of a severe psychiatry illness, such
as schizophrenia and bipolar disorder; as well as a severe
somatic illness were exclusion criteria for all groups. None
of the participants had a history of migraine, epilepsy, or
craniocerebral trauma.
The study was approved by the Ethics Committee of the
Medical Faculty of the University of Bonn. After being
informed of the aim of the study by written and oral de-
scription, all participants gave written informed-consent
statements.
Procedure
Neuropsychological assessment was carried out after writ-
ten informed consent was given by all participants. For the
estimation of verbal intellectual performance, the
Mehrfachwahl-Wortschatz-Intelligenztest (MWT-B) (Lehrl
1999) was used. In addition, a SKID-I interview con-
ducted according to the Diagnostic and Statistical Manual
IV (DSM-IV) procedures was carried out by a psychol-
ogist trained in the use of this instrument to ensure the
absence of present psychiatric disorders in our partici-
pants. Drug history and present pattern of psychotropic
drug consumption were assessed by a structured inter-
view. Subjects who were screened for inclusion in the
drug-naïve control group were urine-tested for drug use.
In addition to the impulsivity and decision-making mea-
sures (see below), the neuropsychological test battery also
comprised a verbal memory task the results of which will
be published elsewhere (Quednow et al. in press). The
whole battery took about 120 min, including breaks as
needed, and was generally well tolerated by the parti-
cipants. During the psychiatric and neuropsychological
assessment, the subjects could ask for a break at any
time.
Interview for psychotropic drug consumption
For the assessment of the use of legal and illegal psy-
chotropic substances, a structured interview was developed
that comprised questions concerning quantity, duration,
and frequency of present and past consumption of all known
psychotropic substances. The quantity of drug consump-
tion was assessed for MDMA in terms of the numbers
of tablets consumed. In addition, one interview question
asked for the highest single MDMA dose ever used (life-
time peak dose). For cannabis, amphetamine, and other
substances, the quantity was measured in terms of the
number of times of use because evaluating and defining
the concept of a single dose was difficult. On the basis of the
actual and former substance intake, we estimated a cu-
mulative drug dose. The data for pattern and amount of drug
consumption of the groups are shown in Table 1.
Neuropsychological assessment
Go/No-Go Task First, participants were administered a
computerized version of the Go/No-Go Task (Go/No-Go
version 1.2; Hiloma Software Development, Montreal,
Canada) in accordance to Newman and Kosson (1986) and
Newman et al. (1990). Participants learned by trial and
error to press a button for “active” stimuli and not to press
for “passive” stimuli. Stimuli, consisting of eight two-digit
numbers (four active, four passive, which ranged from 3 to
99) were repeated ten times in different, randomly as-
signed sequences for a total of 80 trials. Two different sets
of eight numbers were employed (one per condition).
Correct responses were rewarded with a high-pitched tone,
presentation of the word “Richtig” (correct) on the com-
puter screen, and the addition of 10 “Pfennig” (cents) to an
on-screen running tally of the participant’s earnings. In-
correct responses were punished with a low-pitched tone,
presentation of the word “Falsch” (wrong), and subtraction
of 10 Pfennig from the participant’s earnings.
All participants completed two conditions. In the re-
ward–punishment condition, participants began with 1.00
DM (Deutsche Mark). Responses to active numbers were
reinforced, and responses to passive numbers were pun-
ished. In the punishment–reward condition, participants
began with 1.00 DM; nonresponses to active numbers
were punished, and nonresponses to passive numbers were
rewarded. Each condition was preceded by a 12-trial re-
ward pretreatment in which the ratio of active to passive
numbers was 2:1. This pretreatment served to establish
hypothetically a dominant response set for reward
(Newman et al. 1990; LeMarquand et al. 1999).
Participants were given instructions for the GNG, the
reinforcement contingencies, and the process of trial-and-
error learning. With the experimenter present, participants
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completed eight practice trials that involved four pre-
sentations of each of the two practice stimuli (one as an
active number and two as a passive number). The ex-
perimenter was not present during the actual testing. The
order of presentation of the two conditions was the same
for all participants. The experimenter reentered the room
between conditions to explain the expectations for the next
condition.
Dependent measures for this task included commission
errors (failures to inhibit responses to passive numbers)
and omission errors (failures to respond to active numbers)
and total gain in DM. According to the motivational theory
of Gray et al. (1983), impulsive persons make more com-
mission errors because they are less sensitive to punish-
ment and more sensitive to reward, whereas omission
errors are not related to impulsivity (Newman 1987).
Matching Familiar Figures Test Participants were admin-
istered a paper-and-pencil version of the 12-item MFFT
(Kagan et al. 1964; Kagan 1966). The format of the MFFT
involves simultaneous presentation of a stimulus figure
and an array of eight alternatives, all except one differing
in one or more details. The participants were then asked to
select as quickly as possible from the alternatives the figure
that exactly matched the standard. Each participant was
given two practice items followed by 12 test items. If their
initial selection was incorrect, they were told that they
were wrong and were asked to try again. For each subject,
the 12 items were scored according to the time to first
response and the number of errors made before the correct
match. Four dependent variables were analyzed: (1) the
mean latency to first response, (2) the total number of
errors committed, (3) an Impulsivity score (I-score), and
(4) an Efficiency score (E-score). The I-score is a com-
posite index of impulsivity, whereas the E-score reflects
the self-explanatory dimension “fast and accurate” vs “slow
and inaccurate.” Both scores were originally derived by
Salkind and Wright (1977) and later validated by Messer
and Brodzinky (1981). The I-score is calculated by sub-
tracting the standard score of the mean latency to first
response from the standard score of the total number of
errors committed (I-score=Zerror – Zlatency), and the E-score
is calculated by summing the standard score of the mean
latency to first response with the standard score of the total
number of errors committed and a following multiplication
with -1 [E-score = -(Zerror + Zlatency)]. The error and latency
values of all participants were standardized to the means
and standard deviations of the control group.
Decision-making Task After the GNG, participants were
administered a computerized and modified version of the
Iowa GT (Bechara et al. 1994, 1997). The task was pro-
Table 1 Pattern and amount of illegal drug use: results of the psychotropic drug interview
Drug and characteristic MDMA (n=19, ♂) Cannabis (n=19, ♂) Controls (n=19, ♂)
MDMA
Tablets per week 1.97 (2.73) 0.01 (0.05) 0.00 (0.00)
Years of use 3.66 (1.95) 0.11 (0.46) 0.00 (0.00)
Cumulative dose (tablets) 457.9 (433.9) 6.7 (24.0) 0.00 (0.00)
Lifetime peak dosea (tablets) 6.1 (4.7) 0.32 (0.82) 0.00 (0.00)
Last consumption (days) 17.4 (14.6); n=19 504.7 (810.4); n=3 0.00 (0.00)
Cannabis
Times per week 1.63 (1.62) 3.89 (4.72) 0.00 (0.00)
Years of use 3.95 (3.11) 6.55 (3.67) 0.00 (0.00)
Cumulative dose (times) 547.1 (502.7) 1033.4 (1348.6) 0.00 (0.00)
Last consumption (days) 11.1 (21.6); n=16 7.1 (4.7); n=19 0.00 (0.00)
Amphetamine
Times per week 0.82 (1.31) 0.04 (0.16) 0.00 (0.00)
Years of use 3.37 (2.05) 0.63 (1.89) 0.00 (0.00)
Cumulative dose (times) 208.5 (279.5) 14.5 (59.6) 0.00 (0.00)
Last consumption (days) 38.1 (89.9); n=17 240.0 (169.7); n=2 0.00 (0.00)
Cocaine
Times per week 0.04 (0.10) 0.02 (0.06) 0.00 (0.00)
Years of use 0.66 (1.70) 0.26 (0.81) 0.00 (0.00)
Cumulative dose (times) 4.87 (12.51) 2.49 (9.04) 0.00 (0.00)
Last consumption (days) 34.5 (17.2); n=4 17.5 (5.0); n=2 0.00 (0.00)
Hallucinogensb
Cumulative dose (times) 23.4 (38.8) 1.95 (4.24) 0.00 (0.00)
Last consumption (month) 7.86 (9.37); n=14 7.20 (4.60); n=5 0.00 (0.00)
Means and standard deviations in parentheses. Consumption per week, duration of use, and cumulative dose are averaged within the total
group. Last consumption is averaged only for persons who used the drug. In this case, sample size n is shown
aHighest single MDMA dose ever used
bPrimarily LSD and psilocybin were used
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grammed in Turbo Pascal for Windows 95 and Windows
98 by coauthor Christian Hoppe. The GT is a virtual card
game in which participants are told to accumulate as much
play money as possible by picking one card at a time from
any of the four decks (A, B, C, and D) until 100 cards have
been selected. The decks (40 cards each) differ in rep-
resentation of both the level of immediate gain and the
level of penalty risk. In contrast to the original Iowa GT,
the cards had either a gain or a penalty (in the original
version, each card yields a gain, and some cards had an
additional penalty). Gain cards from decks A and B yield
200 points, compared with 100 points for every gain card
from decks C and D. Some cards in each deck carry pen-
alties, such that the accumulated penalties exceed the ac-
cumulated gains in decks A and B, and the accumulated
penalties are smaller than the accumulated gains in decks
C and D. Thus, continued choice from decks C or D leads
to a net gain (1,600 points per deck), whereas continued
choice from decks A or B leads to a net loss (-1,600 points
per deck). The optimal strategy is to avoid the short-term
appeal of the “disadvantageous” decks A and B in favor of
the slower gain from the “advantageous” decks C and D.
Performance on the GT is scored by a global outcome
score (net score) and a score for each consecutive block of
25 cards. These scores correspond to the number of cards
chosen from the advantageous decks (C and D) minus the
number of cards chosen from the disadvantageous decks
(A and B). The analysis of the GT performance by blocks
of 25 cards provides information about the learning
capacity and strategy used by participants (Bechara 2001).
Statistical analysis
Before analyzing the neuropsychological data, we exam-
ined demographic variables. Age, verbal IQ, and years of
education were analyzed using the general linear models
(GLM) approach to analysis of variance (ANOVA) across
all groups as well as t tests for independent samples for
single comparisons to determine whether differences exist-
ed between experimental groups (SPSS, Chicago, IL). The
ratio of smokers and nonsmokers between groups was
analyzed using χ2 tests.
Neuropsychological data were initially analyzed using the
GLM approach to ANOVA across all groups and t tests for
independent samples for single comparisons. In addition, GT
blocks were analyzed using the GLM approach to repeated-
measures ANOVA with GT blocks as dependent variables
(fourfold) and group as a between-subjects fixed factor
(threefoldacrossall groupsor twofoldfor single comparisons).
Correlations of dependent variables with each other,
with demographic variables, and with drug use were tested
using Pearson’s product-moment correlation. Relationships
between neuropsychological variables and drug consump-
tion were analyzed only across combined drug groups. The
confirmatory statistical comparisons of all data across three
groups were carried out at a significance level set at p< .05
(two-tailed). Because of the directional hypothesis of an
elevated impulsivity and disturbed decision making in
MDMA users, single comparisons between MDMA users
and drug-naïve control subjects as well as between MDMA
users and cannabis users were carried out at a significance
level set at p< .05 (one-tailed).
Results
Demographics
The demographic data of the groups are shown in Table 2.
Overall, the three groups did not significantly differ with
respect to age, length of education, and verbal intellectual
performance as measured by the MWT-B (for statistics, see
Table 2). However, because of trends for a different verbal
IQ and length of education, post hoc t tests were applied.
Single comparisons showed that, compared with drug-
naïve control subjects, neither the MDMA nor the cannabis
group differed in length of education and intellectual func-
tioning. However, the MDMA group and the cannabis
group differed significantly with respect to length of
education [t(36) = 2.15, p< .05] and verbal intellectual
performance [t(36) = 2.59, p< .05]. In addition, there were
significantly fewer smokers in the drug-naïve control group
compared with the cannabis group [χ2(1) = 6.76, p< .05]
and the MDMA group [χ2(1)=10.6, p< .001]. Cannabis
users and MDMA users did not differ in their smoking
habits.
Table 2 Demographic data
Total (n=57, ♂) MDMA (n=19, ♂) Cannabis (n=19, ♂) Controls (n=19, ♂) Valuea df/dferr
a pa
Age 24.35 (4.81) 24.21 (5.77) 25.42 (4.26) 23.42 (4.30) F=0.83 2/54 .44
Smoker/nonsmokerb 31/26 15/4 11/8 5/14 χ2=10.75 2 .005
Verbal IQc 105.3 (12.09) 100.6 (11.67) 109.7 (9.47) 105.7 (13.53) F=2.81 2/54 .07
Years of educationc 12.67 (1.41) 12.32 (1.70) 13.21 (0.63) 12.47 (1.54) F=2.29 2/54 .11
Means and standard deviations in parentheses
aANOVA (over all groups) or χ2 test (over all groups) for frequency data
bχ2 test (two-tailed) MDMA vs controls, p<.001; cannabis vs controls, p<.05
ct test (two-tailed) MDMA vs cannabis, p<.05
521
Go/No-Go Task
Initial inspection of the data revealed that several subjects
failed to understand the task instructions because they
performed at a chance level [according to the signal
detection theory of Green and Swets (1966), we used a
criterion of d’<0.25, which is equivalent to 56.5% correct
responses]. Thus, data for 18 MDMA users, 17 cannabis
users, and 15 drug-naïve control subjects were available for
the final analysis.
Omission and commission errors as well as gain in each
condition were also summed into total scores (Table 3).
Errors within the 12-trial, reward-pretreatment phase were
not included because participants had to be exposed to the
stimuli at least once in order to learn which were active and
passive.
An initial ANOVA did not reveal any significant main
effect between the groups in the dependent variables (for
statistics, see Table 3). Single comparisons with the t test
for independent samples (one-tailed) showed a signifi-
cantly elevated commission error rate [punishment-reward
condition: t(33) = 1.74, p< .05; summed conditions: t(33) =
1.73, p< .05] as well as a lower gain [punishment-reward
condition: t(33) = –1.67, p< .05; summed conditions: t(33)
< –1.87, p < .05] in MDMA users in comparison with
cannabis users. MDMA users and drug-naïve controls, as
well as cannabis users and drug-naïve control subjects, did
not differ significantly in the dependent variables of the
GNG. The GNG variables were not correlated with age,
years of education, or verbal IQ.
Variables from the single GNG conditions were not cor-
related with drug consumption separately because the
analysis would suffer either from capitalization on chance
or from the overly conservative alpha levels that would be
needed to correct for test multiplicity. Across drug groups,
the summed gain was correlated with years of amphet-
amine use (r= –.44, n=35, p<.01), years of MDMA use
(r= –.35, n=35, p<.05), cocaine use per week (r= –.38,
n=35, p< .05), and years of cocaine use (r= –.35, n=35,
p<.05). Summed commission errors were correlated with
the cumulative cannabis dose (r=.36, n=35, p<.05), years
of amphetamine use (r=.44, n=35, p<.01), cocaine use per
week (r=.45, n=35, p<.01), years of cocaine use (r=.59,
n=35, p<.001), and the cumulative cocaine dose (r=.42,
n=35, p<.05). Summed omission errors were not correlated
with drug consumption. In both groups, only 19 participants
reported an instance of amphetamine use, and only six
participants reported an instance of cocaine use. Thus,
statistical correlations with these substances should be in-
terpreted with caution. The period of abstinence of any
illegal drug did not correlate with the variables of the GNG.
In summary, MDMA users made significantly more
commission errors than did cannabis users. However, this
difference could be explained by an increased performance
of the cannabis group rather than by an elevated im-
pulsivity of the MDMA group because MDMA users and
drug-naïve control subjects show a comparable perfor-
mance in this task.
Matching Familiar Figures Test
Data for 19 MDMA users, 19 cannabis users, and 19 drug-
naïve control subjects were available for this analysis. The
I-score (r= –.28, n= 57, p< .05) as well as mean latency to
first response (r= .38, n= 57, p< .01) were significantly
correlated with age (i.e., impulsivity decreases and reaction
time slows down as age increases). This relationship of age
and impulsivity is a well-known phenomenon with regard
to the MFFT (Kirchner-Nebot and Amador-Campos 1998).
Thus, analyses of these variables had to be corrected for age.
An initial ANOVA (reaction time and I-score corrected
for age) revealed no significant main effect between the
groups in the dependent variables (for statistics, see
Table 4). Yet because we wanted to test a directional
hypothesis, we’ve also done single comparisons with the t
Table 3 Scores on the Go/No-Go Task of MDMA users, cannabis users, and drug-naïve controls
Condition MDMA (n=18, ♂) Cannabis (n=17, ♂) Controls (n=15, ♂) F a df/dferr
a pa
Reward-punishment
Omission errors 3.06 (3.25) 4.00 (5.31) 3.53 (3.66) 0.22 2/47 .81
Commission errors 12.83 (6.50) 11.00 (5.91) 11.26 (5.96) 0.45 2/47 .64
Gain 3.70 (0.73) 3.96 (0.73) 3.86 (0.93) 0.47 2/47 .63
Punishment-reward
Omission errors 6.94 (4.75) 6.12 (4.94) 6.97 (5.60) 0.12 2/47 .89
Commission errorsb 9.28 (4.80) 6.29 (5.36) 9.60 (8.16) 1.46 2/47 .24
Gainb 3.16 (0.87) 3.65 (0.87) 3.25 (1.41) 1.04 2/47 .36
Summed conditions
Σ omission errors 10.94 (6.83) 9.18 (5.69) 10.20 (7.70) 0.30 2/47 .74
Σ commission errorsb 22.11 (9.44) 17.29 (6.75) 20.87(12.87) 1.12 2/47 .34
Σ gainb 6.86 (1.26) 7.61 (1.12) 7.11 (2.12) 1.09 2/47 .35
Means and standard deviations in parentheses
aANOVA (over all groups)
bt test (one-tailed) MDMA vs cannabis, p<.05
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test for independent samples (one-tailed) with respect to the
I-score. After correcting the raw values for age, this anal-
ysis did show a significantly increased I-score [t(36) = 1.66,
p< .05] in MDMA users in comparison with drug-naïve
control subjects. However, MDMA users and the cannabis
users did not significantly differ in the I-score [t(36) = 1.21,
p= .12 (one-tailed)], and cannabis users did not show a
significant elevation of the I-score compared with controls
[t(36) = 0.71, p= .48 (two-tailed)].
Across drug groups, the mean latency to first response
(r= –.48, n= 22, p< .05) as well as the I-score (r= .48,
n= 22, p< .05) was significantly correlated with the
lifetime peak dose of MDMA, indicating that high single
doses of MDMAwere associated with a faster reaction time
and an elevated impulsivity in the MFFT. In addition,
cumulative amphetamine doses correlated with the number
of errors (r= .33, n= 38, p< .05), and the years of cannabis
use were associated with reaction time (r= .36, n= 38,
p< .05). Finally, the cumulative hallucinogen dose was
correlated with the E-score (r= –.38, n= 38, p< .05). The
period of abstinence of any illegal drug also did not
correlate with the MFFT variables. Thus, acute drug effects
are unlikely to account for the elevated impulsivity of the
MDMA users.
In summary, MDMA users showed an elevated im-
pulsivity in the MFFT compared with drug-naïve control
subjects, whereas cannabis users and control subjects had
comparable I-scores. In addition, high single doses of
MDMA were associated with higher I-scores and a faster
reaction time.
Decision-making Task
One MDMA user had previously executed the GT and was
therefore excluded from this analysis. Thus, data for 18
MDMA users, 19 cannabis users, and 19 drug-naïve con-
trol subjects were available for analysis. Performance of the
experimental groups on the GT is shown in Fig. 1. An
ANOVA of the GT net score across all groups showed a
significant main effect of the factor group [F(2,53) = 4.78,
p< .01]. Single comparisons (one-tailed) of the net score
revealed that the MDMA users performed significantly
worse compared to drug-naïve controls [t(35) = –2.04,
p< .05] as well as compared with the cannabis group [t
(35) = –3.28, p< .001]. Cannabis users and control subjects
did not differ in terms of the net score. An ANOVA [block
× group, with repeated measures at factor block (fourfold)]
with GT blocks across all groups revealed a significant
main effect of the factor block [F(3,159) = 22.8, p< .001],
reflecting the strategy shift across blocks and a significant
interaction of factor blocks and group [F(6,159) = 2.21,
p< .05], indicating differences in deck preferences across
blocks between the groups. There was also a significant
between-subject effect [F(2,53) = 4.78, p< .01], indicating
different preferences of decks in total between the groups.
Single comparisons with ANOVA [block × group, with
repeated measures at factor block (fourfold)] showed a
significant between-subject effect [F(1,35) = 4.17, p< .05]
and a significant interaction of both factors [F(3,105) =
2.87, p< .05] between MDMA users and drug-naïve
control subjects. In addition, the analysis revealed a
significant between-subject effect between MDMA users
and cannabis users [F(1,35) = 10.7, p< .01], but in this
comparison, the interaction of both factors was not
significant [F(3,105) = 2.05, p= .11]. Cannabis users and
drug-naïve control subjects did not differ in repeated-
measures ANOVA. In all single comparisons, the main
effect of the factor block was significant to a level of at
least p< .01. Performance on the GT was not correlated
with age, years of education, or verbal IQ.
In the fourth block, the ratios of good and bad decks
converge in all groups (Fig. 1). The explanation for this
Fig. 1 Performance on the Gambling Task of MDMA users.
Cannabis users and drug-naïve controls scored by a global outcome
score (net score) and a score for each consecutive block of 25 cards
(means±standard error of means). *t test (one-tailed) p<.05, **t test
(one-tailed) p<.001
Table 4 Scores on Matching Familiar Figures Task of MDMA users, cannabis users, and drug-naïve controls
MDMA (n=19, ♂) Cannabis (n=19, ♂) Controls (n=19, ♂) F a df/dferr
a pa
Σ errors (number) 8.16 (4.09) 5.95 (4.36) 6.47 (4.23) 1.42 2/54 .25
Mean latency to first responseb (s) 49.5 (19.3) 53.3 (21.7) 60.5 (29.9) 1.81 2/53 .17
Impulsivity scoreb,c (z-score) 0.76 (1.43) 0.12 (1.49) 0.00 (1.77) 1.49 2/53 .23
Efficiency score (z-score) −0.03 (0.82) 0.36 (0.99) 0.00 (0.93) 1.10 2/54 .34
Means and standard deviations in parentheses
aANOVA (over all groups)
bThe mean latency to first response and the Impulsivity score were significantly correlated with age; therefore, ANOVAs were corrected for
age in these variables
ct test (one-tailed, raw values corrected for age) MDMA vs controls, p< .05; MDMA vs cannabis, p = .12
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effect is that both advantageous and both disadvantageous
decks have a maximum of 80 cards in total. Thus, if sub-
jects demonstrated an early preference for only one of the
two deck types, they had to draw cards from the remaining
decks at the end. Thus, a good decision-making strategy
will be punished and a bad strategy rewarded in the last
block. A repeated-measures ANOVA across only the first
three blocks reveals, therefore, stronger interaction effects
between factor blocks and group despite lower statistical
power due to fewer degrees of freedom [all groups: F
(4,106) = 2.96, p= .02; MDMAvs controls: F(2,70) = 5.41,
p=.007; MDMA vs cannabis: F(2,70) = 2.69, p=.08;
cannabis vs controls: F(2,72) = 1.26, p=.29].
Across drug groups, the GT net score was correlated
only with years of MDMA use (r= -.34, n= 37, p< .05),
indicating that a long period of MDMA use was associated
with impaired decision-making performance in the GT.
Other illegal drug use patterns did not significantly cor-
relate with the GT performance. Furthermore, the period of
abstinence from any illegal drug did not correlate with the
GT performance. Thus, acute drug effects are unlikely to
account for the impaired decision-making cognition of the
MDMA users.
In summary, MDMA users performed significantly worse
in the GT compared with both cannabis users and drug-
naïve control subjects. However, cannabis users and control
subjects did not differ in their decision-making perfor-
mance. In addition, a longer duration of MDMA use was
associated with a worse decision-making performance.
Correlations between impulsivity
and decision-making tasks
Table 5 shows the Pearson’s product-moment correlations
between the two impulsivity tasks and the decision-making
task. The GT net score was highly correlated with the I-
score of the MFFT as well as with the commission errors in
the GNG, supporting the mutual interdigitation of the
impulsivity and decision-making concepts. Furthermore,
GNG commission errors were also highly correlated with
the MFFT I-score, suggesting that these measures tap into
similar cognitive mechanisms. It also appears that the
MFFT error score, rather than the reaction time, was related
to GNG commission errors and to the GT net score.
Discussion
The aim of this study was to analyze the effect of MDMA
use on impulsivity and decision-making cognition. MDMA
users showed significantly higher impulsivity in the MFFT
I-score but not in commission errors made on the GNG
compared with drug-naïve control subjects. Cannabis users
and drug-naïve control subjects did not differ in impulsiv-
ity measures. In the GT, MDMA users showed a signif-
icantly lower decision-making performance than cannabis
consumers or drug-naïve control subjects, whereas the
decision-making performance of cannabis users was sim-
ilar to that of drug-naïve control subjects. To the best of our
knowledge, our study is the first to highlight decision-
making deficits in MDMA users. Furthermore, the MFFT
performance was correlated with a lifetime peak dose of
MDMA, and the decision-making performance was cor-
related with years of MDMA intake. These associations
suggest that the elevated impulsivity and the disrupted
decision-making performance are a consequence of the
MDMA intake. In addition, the I-score and the decision-
making performance were correlated, indicating that the
decision-making deficit of MDMA users may be attributed
to an acquired lack of inhibitory control. It has to be
emphasized that the MDMA users examined in the present
study were mostly heavy users (at least 50 times of use,
with an apparent mean of over 450 lifetime uses).
Impulsivity
MDMA users showed a significantly increased impulsivity
in the MFFT but not in the GNG. This dissociation in-
dicates that these tasks reflect different aspects of cognitive
impulsivity. It was proposed that several behavioral im-
pulsivity paradigms describe different facets of impulsivity
(Monterosso and Ainslie 1999; Moeller et al. 2001; Swann
et al. 2002). According to the taxonomy of Moeller et al.
(2001), the MFFT is among the response disinhibition/at-
tentional paradigms, whereas passive avoidance learning
tasks like the GNG according to Newman and Kosson
(1986) would be assigned to the punishment and/or extinc-
tion paradigms. This concept is of special interest because
it was previously shown that only the response disinhibi-
tion/attentional paradigms, but not the punishment and/or
Table 5 Pearson’s product-moment correlations between impulsivity measures (MFFT, Go/No-Go Task) and the Decision-Making Task
(Gambling Task)
n=57a MFFT errors MFFT reaction time MFFT I-score MFFT E-score Gambling Task net score
Gambling Task, net score −.42 .29 −.42 –
Go/No-Go Task, total gain −.38 −.33 .28 .42
Go/No-Go Task, commission errors .36 .34 −.49
The table shows only the task pairs with correlation coefficients falling below a significance level of p < .05. Correlation coefficients falling
below a significance level of p<.01 are bold
aMFFT n=57, Gambling Task n=56, Go/No-Go Task n=50
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extinction paradigms, were associated with 5-HT function
(Puumala and Sirviö 1998; Evenden 1999; Harrison et al.
1999; Moeller et al. 2001). Thus, a selective serotonergic
neurotoxicity of MDMA could have manifested only in the
MFFT but not in the GNG performance. However, both
tasks indeed seem to measure facets of the same construct
because the MFFT I-score and the GNG commission errors
were positively correlated.
This study replicates previous findings of elevated cog-
nitive impulsivity in the MFFT in MDMA users (Morgan
1998; Morgan et al. 2002), and in accordance with the
findings of Fox et al. (2002) [who used the Cambridge
Neuropsychological Test Automated Battery (CANTAB)
Go/No-Go Task], we could not demonstrate changes in the
MDMA users’ GNG commission error rate. Thus, also
across previous studies, the dissociation of both impulsiv-
ity measures appeared. It should be noticed that the effect
sizes of the MFFT I-score in our study were smaller
(d=0.49) than in the study conducted by Morgan (1998)
(d=0.66). This finding may be explained by the fact that
Morgan (1998) and Morgan et al. (2002) used the longer
20-item version of the MFFT of Cairns and Cammock
(1978). The 12-item MFFT used here is in fact valid
(Arizmendi et al. 1981; van den Broek et al. 1987), but it is
less reliable than the 20-item version (Loper and Hallahan
1980). The lower reliability of the 12-item version could
explain the different effect sizes. Future studies should
therefore use the longer 20-item version.
Functional imaging studies suggested that several brain
regions are involved in behavioral inhibition. In these
studies, the prefrontal, the inferior parietal, and the cin-
gulate cortices were consistently activated during inhibi-
tion of reactions (Liddle et al. 2001; Lee et al. 2001; Rubia
et al. 2001, 2003; Garavan et al. 2002; Watanabe et al.
2002; Horn et al. 2003). Furthermore, patients with wide
frontal lesions exhibit an increase in impulsive behavior
(Miller and Milner 1985; Miller 1985, 1992), and it was
recently shown that patients with selective orbitofrontal
lesions revealed an increased impulsivity as measured with
the MFFT (Berlin et al. 2004). Thus, the elevated im-
pulsivity of MDMA users may be ascribed to an impair-
ment of frontal, inferior parietal, or cingulate regions. This
view is supported by results of animal studies showing that
the frontal regions in particular exhibit a sustained loss of
5-HT axon terminals after MDMA exposure (Fischer et al.
1995; Hatzidimitriou et al. 1999). In addition, immunohis-
tochemical studies indicate that MDMA appears to cause a
selective degeneration of fine-diameter serotonergic axons
with small varicosities that arise from the dorsal raphe
nucleus and that project particularly into the forebrain. In
contrast, 5-HT-containing axons with large round varicos-
ities and small intervaricose segments that arise predomi-
nantly from the median raphe nuclei appear to be unaffected
by MDMA (O’Hearn et al. 1988; Wilson et al. 1989).
Acute drug effects were unlikely to account for the ele-
vated impulsivity of MDMA users because the mean
period of abstinence of MDMA was 17.4 days (median=
14 days) and the elimination half-life of MDMA in
humans is relatively short, with about 8–9 h (de la Torre
et al. 2000). In addition, no correlation between im-
pulsivity measures and period of abstinence was found.
Furthermore, we found no alteration of impulsivity in
chronic but presently abstinent cannabis users. To the best
of our knowledge, this is the first published study involving
cannabis users and behavioral measures of impulsivity.
Acute administration of Δ9-tetrahydrocannabinol (THC)-
one of the psychoactive components of cannabis-increased
impulsive responding on the Stop Task but did not affect
other impulsivity measures such as the GNG (McDonald et
al. 2003). However, it is unlikely that the elevated im-
pulsivity of MDMA users is caused by postacute cannabis
effects because we found no increased impulsivity in the
cannabis group, although that group had a smaller mean
duration of cannabis abstinence as well as a more intensive
cannabis consumption than the MDMA group.
Decision-making cognition
In contrast to the findings of Fox et al. (2002), we could
demonstrate decision-making deficits in MDMA users.
However, there are some differences between the studies:
In this study, the cumulative MDMA dose of the users was
2.5-fold larger than that of the MDMA users described by
Fox et al.; thus, a behavioral neurotoxic effect was possibly
more penetrating in our study. Otherwise, the decision-
making tasks in both studies were very different. The
Decision-Making Task of Rogers et al. (1999a) is more
complex and requires a higher intellectual performance
level than the GT according to Bechara et al. (1994). In a
previous study analyzing three decision-making tasks, the
Rogers task was strongly correlated with IQ, whereas no
association of the Bechara task with IQ was found
(Monterosso et al. 2001). We also could not determine a
correlation between GT performance and verbal IQ. An-
other difference is that no learning of reinforcement con-
tingencies by trial-and-error is needed in the Rogers task;
thus, the Rogers task rather measures risk-taking behavior
in association with analytical skills and less so the ability
for long-term maximization of profit as the Bechara task
does. In addition, Monterosso et al. (2001) could show in
cocaine-dependent subjects that both tasks did not cor-
relate. In summary, the Rogers task measures “cognitive”
or “executive” components, whereas the Bechara focuses
on “impulsive” and “emotional” components of decision-
making performance (Monterosso et al. 2001). This as-
sumption is partly supported by the correlation of the MFFT
I-score with the GT performance results reported here.
A comparable finding was reported by Paulus et al.
(2002, 2003): Users of methamphetamine, which has sero-
tonergic as well as dopaminergic neurotoxic effects, have
also shown decision-making deficits.
On the basis of lesion studies, the orbitofrontal/ven-
tromedial (Eslinger and Damasio 1984; Damasio et al.
1991; Shallice and Burgess 1991; Bechara et al. 1994;
Rogers et al. 1999b) and the dorsolateral/dorsomedial pre-
frontal cortices (Ernst et al. 2002; Manes et al. 2002) were
suggested as key structures for decision-making cognition.
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Paulus et al. (2002) demonstrated in an fMRI study that
methamphetamine users showed significantly less activa-
tion of the orbitofrontal/ventromedial prefrontal cortex during
a decision-making task than controls. The authors inter-
preted their findings as a consequence of methamphet-
amine neurotoxicity. Accumulating evidence suggests that
several amphetamine derivates can cause decision-making
deficits by sustained modulation of serotonergic and do-
paminergic projections in frontolimbic and frontostriatal
circuits (Jentsch and Taylor 1999; Rogers et al. 1999b,
Paulus et al. 2002). Because of these previous findings, we
propose that the decision-making deficits of MDMA users
are based on alterations of their orbitofrontal/ventromedial
and/or dorsolateral/dorsomedial prefrontal cortex caused
by MDMA.
To accomplish a gambling task, multiple cognitive and
emotional processes are involved, including remembering
past outcomes, learning long-term contingencies, evaluat-
ing immediate wins relative to long-term losses and, final-
ly, choice mechanisms regulating the decision maker’s
impulsiveness and recklessness (Busemeyer and Stout
2002). A decrease in inhibitory control would therefore
lead to an impaired decision-making performance. We con-
firmed this relationship in the correlation of GT performance
with MFFT I-score as well as with commission errors made
in the GNG. Thus, the decision-making deficit of MDMA
users is probably because of the loss of inhibitory control.
Again, acute drug effects were unlikely to account for
the decision-making deficits of MDMA users because the
mean period of abstinence of MDMA and other drugs was
too long (see above) and we found no correlation between
the GT performance and the period of drug abstinence.
In contrast to a previous study (Whitlow et al. 2004), we
could not find decision-making deficits with the GT in
cannabis users. However, the heavy cannabis users de-
scribed by Whitlow et al. (2004) had to abstain from can-
nabis use only for at least 12 h before testing, which is a
very short period of time, because THC plasma elimination
half-lives are known to range from 18 to 50 h (Huestis and
Cone 1998). As described above, acute THC can increase
some aspects of impulsivity (McDonald et al. 2003); thus,
the decision-making deficit of the cannabis users in the
study conducted by Whitlow et al. was probably caused by
acute drug effects. However, it is unlikely that postacute
cannabis effects influenced the decision-making cognition
of our MDMA group because (1) our participants had to
abstain from cannabis use for at least 3 days before testing
and (2) we found no alterations in decision-making per-
formance in the cannabis group, although they had a smal-
ler mean duration (7.1 days) of cannabis abstinence than
the MDMA group (11.1 days) as well as a more intensive
cannabis consumption.
Neurotoxicity or predisposition?
Cognitive functions have been proposed as sensitive mark-
ers of neurotoxicity (Paule 1995). A fundamental concept
of toxicology is the dose-response relationship, which states
that there is a direct relationship between the amount of a
toxic noxa to which an individual or a group is exposed and
a toxic (behavioral) effect (Rosenberg 1995). Thereby, the
dose of a toxic drug can be measured in different ways,
e.g., peak, weekly or cumulative dose, but also in fre-
quency or length of use. In this study, it was demonstrated
that the significantly elevated impulsivity of MDMA users
and the significantly disturbed decision-making cognition
were associated with the lifetime peak dose of MDMA and
the years of MDMA intake, respectively. These dose-
response relationships suggest that the cognitive deficits
are a consequence rather than a predisposition. Further-
more, the correlation with the MDMA peak dose is in line
with animal data that high or frequent doses of MDMA
might be required to produce neurotoxic damage (O’Shea
et al. 1998).
It was plausibly argued that people may start and con-
tinue to abuse drugs just because they are more impulsive,
are risk seekers, and are bad decision makers. Thus, higher
impulsivity and worse decision-making cognition would be
vulnerability factors for every type of drug abuse (Bechara
et al. 2001; Bechara and Damasio 2002; Ernst et al. 2003).
However, we could not show impulsivity and decision-
making deficits in regular cannabis users, a finding that
disproves the assumption that drug abuse in general had to
be associated with higher levels of impulsivity or dys-
functional decision making. Our data, instead, support the
notion that an increase in impulsivity and a decline in
decision-making cognition in amphetamine derivate users
resulted from the serotonergic or dopaminergic neurotox-
icity of these substances (Jentsch and Taylor 1999; Rogers
et al. 1999b; Paulus et al. 2002). With respect to cocaine,
Bolla et al. (1998, 1999) pointed out that both the pre-
disposition of a cognitive style and the neurotoxicity of the
substance may have an interactive strengthening effect.
Maybe this applies also for the amphetamine derivates.
However, cross-sectional designs, such as the one used in
this study, are less suitable to prove both assumptions ade-
quately. Longitudinal designs measuring behavioral im-
pulsivity and decision-making cognition in MDMA users
(ideally before the onset of stimulant use or after long-term
abstinence) are required to determine whether impulsive
behavior leads to stimulant use or vice versa. Furthermore,
cross-sectional designs cannot answer the question regard-
ing the reversibility of the neurotoxic effects of MDMA.
Again, only longitudinal designs can enlighten this issue.
In contrast to the findings in MDMA users, nonhuman
primates exposed to high-dose repeated regimens of MDMA
surprisingly do not exhibit cognitive deficits under normal
conditions, although 5-HT markers in several neocortical
brain regions were decreased by 50–90% (Frederick et al.
1998; Taffe et al. 2001; Winsauer et al. 2002). However,
Taffe et al. (2001, 2003) reported that the brains of
MDMA-treated monkeys were not functionally intact
because alterations in brainstem auditory evoked potentials
(BSAEP) persisted up to 13 weeks following MDMA ex-
posure. In addition, it was shown that MDMA-treated
monkeys revealed strong behavioral deficits under an ad-
ditional challenge to the 5-HT system (Frederick et al.
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1998; Taffe et al. 2002, 2003). But how can the discrepancy
between the dramatic decrease in 5-HT brain levels and the
lack of behavioral consequences under normal conditions
be explained? Frederick and Paule (1997) summarized some
possible difficulties in detection of behavioral neurotoxic-
ity of MDMA in laboratory animals: “the treatment reg-
imens used did not sufficiently damage the 5-HT system
enough to alter the observed behaviors; other brain regions
functionally compensate for any damage that is induced;
the behaviors that were monitored were not subserved by
the 5-HT system; or, the behavioral tasks used were not
sensitive to changes in the 5-HT system” (p. 72). Thus,
further animal studies on cognitive neurotoxicity of MDMA
should apply cognitive test batteries which are more similar
to the tests with which cognitive deficits in MDMA users
have been shown.
One limitation of this study is that the history of drug
consumption was assessed using only subjective reports. A
drug-usage screening would be desirable to better control
for acute and postacute drug effects within a few days of
the assessment. A related and so far unsolved problem is
that the exact consumption pattern of drugs across an in-
dividual’s lifetime is not objectively calculable (Curran,
2000). However, Stuerenburg et al. (2002) found a con-
cordance of 91.3% between the self-reported drug intake
and toxicological analyses of hair specimens in a sample of
German MDMA users.
Due to the use of cannabis users as a “clinical” control
group, we could largely rule out cannabis use as potential
confound of our results. Nevertheless, our MDMA users
also reported some use of amphetamine. However, the
amount of amphetamine use was relatively small (∼3.5
times per month) compared to the MDMA use (∼8.5 tablets
per month) especially because every single “line” of sniffed
amphetamine (which is a very small quantity) was doc-
umented as one time of use. Furthermore, the MFFT
I-score as well as the performance in the GT was not cor-
related with indicators of amphetamine use but only with
MDMA use, although MDMA use and amphetamine use
were highly intercorrelated in our MDMA users (cumula-
tive doses: r=.57, n=19, p<.01; weekly doses: r=.80, n=19,
p<.001). Thus, we think that MDMA and not amphetamine
is the denominator with respect to the shown deficits in
impulsivity and decision-making cognition. However, it
should also be noticed that possible drug-drug interactions
could not completely be excluded in such study design
based on “real-life conditions”.
In summary, our results provide, to the best of our
knowledge, the first evidence of a decision-making deficit
on the basis of an increased behavioral impulsivity in
heavy but presently abstinent users of MDMA. Associa-
tions with the amount of MDMA consumption and the fact
that MDMA is a neurotoxin selective for the 5-HT system
suggest that these behavioral deficits were acquired via
MDMA use. Furthermore, the concomitant cannabis use of
the MDMA users could not account for the behavioral
deficits because (1) cannabis users did not show changes in
impulsivity or decision-making performance and (2)
parameters of cannabis use were not statistically correlated
with impulsivity and decision-making measures. Our data
also suggest that the elevated impulsivity and the decision-
making deficits of MDMA users could likely be attributed
to a dysfunction of regions within the frontal cortex. Thus,
the cognitive deficits of MDMA users could not be
explained exclusively because of an impairment of
temporal regions, as has been proposed by some
researchers (Fox et al. 2002; Gouzoulis-Mayfrank et al.
2003; Daumann et al. 2004; Jacobsen et al. 2004).
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